Clinical trials: Depression Symptom
Generalized Anxiety Disorder
A Study To Assess Adverse Events and Change in Disease Activity With Oral Cariprazine When Added to Antidepressant Therapies (ADTs) Compared to Placebo in Adult Participants With Generalized Anxiety Disorder (GAD) Who Have Had an Inadequate Response to ADTs Alone
Generalized anxiety disorder (GAD) is usually treated with antidepressant therapy (ADT); however, sometimes ADTs alone are not enough to adequately treat GAD.
- Trial name
- CAR aGAD Ph 2 (NCT04965272)
- Testing
- Cariprazine 0.75 mg/day, Cariprazine 1.5 mg/day, Cariprazine 3.0 mg/day
- Where
- 36 sites in United States
- Sponsor
- AbbVie
Depression, Teen
Digital Therapeutic vs Psychoeducation for Management of Mild to Moderate Depression in Adolescents
The purpose of the present randomized controlled study is to investigate if there is a difference in depression symptoms at 4-weeks among adolescents ages 16-17 years assigned to W-GenZD, a digital therapeutic, as compared to a…
- Trial name
- NCT04985331
- Testing
- W-GenZD
- Where
- United States
- Volunteers
- 246 people
- Sponsor
- Woebot Health
Depressive Disorder, Major, Diabetic Neuropathies
Study Evaluating the Potential of DVS SR to Inhibit the CYP2D6 Pathway
To evaluate the effects of multiple oral doses of desvenlafaxine sustained release (DVS SR) and paroxetine on the biotransformation of codeine to morphine in healthy subjects.
- Conditions
- Depressive Disorder, Major, Diabetic Neuropathies, Fibromyalgia, Vasomotor Symptoms
- Trial name
- NCT00456898
- Testing
- desvenlafaxine sustained release (DVS SR), Paroxetine, Codeine
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Major Depressive Disorder, MDD
A Non Interventional Study to Investigating the Ratio of Mis-diagnosed Bipolar Symptoms in Patient With Major Depressive Disorder (MDD)
The study will only detect hypomanic symptoms in treatment resistant MDD patients by mean of HCL-32 administration. Further re-evaluation of MDD diagnosis is not a direct aim of the study.
- Trial name
- Improve (NCT01344733)
- Where
- 29 sites in Italy
- Volunteers
- 660 people
- Sponsor
- AstraZeneca
Refractory Major Depressive Disorder
A Long Term Study of ALKS 5461 in the Treatment of Refractory Major Depressive Disorder (MDD)
This study will assess the long-term safety and tolerability of ALKS 5461 as an adjunctive treatment for refractory MDD.
- Trial name
- NCT03610048
- Testing
- ALKS 5461
- Where
- 34 sites in United States, Australia and 1 more
- Volunteers
- 175 people
- Sponsor
- Alkermes, Inc.
Depression, Post Traumatic Stress Disorder
Ketamine and Epigenetic Aging
This is a prospective, clinical pilot study (n=20) to evaluate the impact of a ketamine treatment for Major Depressive Disorder (MDD) or Post Traumatic Stress Disorder (PTSD) on epigenetic aging by the TruAge epigenetic age…
- Trial name
- NCT05294835
- Testing
- Ketamine
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- TruDiagnostic
Depression, Postpartum, Postpartum Depression (PPD)
Brexanolone Lifting Outcomes Of Moms
The purpose of this research study is to test the study drug, LPCN 1154A, as a possible treatment for postpartum depression (PPD).
- Conditions
- Depression, Postpartum, Postpartum Depression (PPD), Post-partum Depression, Postnatal Depression
- Trial name
- BLOOM (NCT07822321)
- Testing
- LPCN 1154A
- Where
- 16 sites in United States
- Volunteers
- 120 people
- Sponsor
- Lipocine Inc.
Depression
Fevarin® Effectiveness in Treatment of Depression in Patients With Neurological Disorder
Prospective, multicenter, non-comparative, observational program to describe prevalence of depressive symptoms in a variety of neurological disorders and effects of Fevarin® on the severity of anxiety and depression, sleep state…
- Trial name
- FRIENDS (NCT02043197)
- Where
- 29 sites in Russia
- Volunteers
- 300 people
- Sponsor
- Abbott
Major Depressive Disorder With Excessive Daytime Sleepiness Symptoms
Clinical Assessment of Response in the Treatment of Depression With Daytime Sleepiness Using Solriamfetol
CLARITY (Clinical Assessment of Response in the Treatment of Depression with Daytime Sleepiness Using Solriamfetol) is a Phase 3, double-blind, placebo-controlled, multicenter randomized withdrawal trial in patients with major…
- Trial name
- CLARITY (NCT07484217)
- Testing
- Solriamfetol 150 MG
- Where
- 40 sites in United States
- Volunteers
- 508 people
- Sponsor
- Axsome Therapeutics, Inc.
Depressive Disorder, Major Depression
A Study of SR58611A in the Prevention of Depression Relapse in Patients With Major Depressive Disorder
The purpose of the study is to assess whether treatment with SR58611A can prevent relapse of depressive symptoms in patients with major depressive disorder.
- Trial name
- CALYPSO (NCT00345098)
- Testing
- SR58611A
- Where
- 13 sites in Argentina, Bulgaria and 11 more
- Volunteers
- 704 people
- Sponsor
- Sanofi
Sleep Disorder (Disorder), Anxiety Depression Disorder
The Effect of Avnace eZZe on Sleep Improvement
This study aims to examine the effectiveness of Avance eZZe drink with liposomal technology in improving sleep quality. Participants will be randomly assigned to either the placebo group, Avance eZZe drink group, and Avance eZZe…
- Trial name
- NCT07172607
- Testing
- Avance eZZe drink, Avance eZZe drink (without liposomal)
- Where
- Taiwan
- Volunteers
- 75 people, healthy volunteers welcome
- Sponsor
- TCI Co., Ltd.
Depression
A Study of the Effectiveness and Safety of JS1-1-01 Tablet in Patients With Moderate to Severe Depression
The purpose of this study is to evaluate the Effectiveness and Safety of JS1-1-01 Tablet in Patients With Moderate to Severe Depression
- Trial name
- NCT07485595
- Testing
- JS1-1-01 low-dose group, JS1-1-01 high-dose group
- Where
- China
- Volunteers
- 180 people
- Sponsor
- Tasly Pharmaceutical Group Co., Ltd
Major Depressive Disorder
Study to Assess the Efficacy and Safety of NBI-1065845 in Adults With Major Depressive Disorder (MDD)
The purpose of this study is to evaluate the efficacy of NBI-1065845 compared with placebo in participants with MDD on improving symptoms of depression.
- Trial name
- SAVITRI (NCT05203341)
- Testing
- NBI-1065845
- Where
- 41 sites in United States, Bulgaria and 4 more
- Volunteers
- 183 people
- Sponsor
- Neurocrine Biosciences
MDD, Anxiety Disorders
Vortioxetine in Patients With Depression Coexisting With General Anxiety Disorder (GAD)
This study evaluates the effectiveness of vortioxetine on depressive symptoms in patients with depression coexisting with generalized anxiety disorder.
- Trial name
- RECONNECT (NCT04220996)
- Testing
- Vortioxetine
- Where
- 21 sites in Estonia, France and 4 more
- Volunteers
- 100 people
- Sponsor
- H. Lundbeck A/S
Depression
Post Marketing Study to Evaluate the Resource Utilization of Patients Suffering From Resistant Depression Treated With Deep TMS in Comparison to Treatment as Usual
The aim of the study is to evaluate the efficacy of the Deep TMS compare to TAU and the different in resource utilization of treating depression with Deep TMS compare to the TAU.
- Trial name
- NCT02260765
- Testing
- dTMS
- Where
- United States
- Sponsor
- Brainsway
Major Depressive Disorder
A Randomized Study of Azetukalner Versus Placebo in Major Depressive Disorder (X-NOVA3)
X-NOVA3 is a Phase 3, multicenter, randomized, double-blind, placebo-controlled study to evaluate the clinical efficacy, safety, and tolerability of azetukalner as a monotherapy in adult participants diagnosed with Major…
- Trial name
- X-NOVA3 (NCT07076407)
- Testing
- Azetukalner
- Where
- 50 sites in United States, Finland and 5 more
- Volunteers
- 450 people
- Sponsor
- Xenon Pharmaceuticals Inc.
Impotence, Depression
Efficacy Study Measuring The Impact Of Treatment With Viagra On The Depressive Symptoms Of Men With Erectile Dysfunction
This study will measure the impact of treatment with Viagra on the depressive symptoms and quality of life in men with erectile dysfunction who have untreated depressive symptoms meeting the DSM-IV criteria for dysthymia or…
- Trial name
- NCT00159809
- Testing
- Viagra (Sildenafil citrate)
- Volunteers
- 140 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Major Depressive Episode (MDE), Major Depressive Disorder (MDD)
A Study to Evaluate TNX-102 SL Monotherapy Versus Placebo in Participants With Major Depressive Disorder (MDD)
The goal of this clinical trial is to learn if a drug called TNX-102 SL works to treat moderate to severe major depressive disorder in adults. It will also learn about the safety of TNX-102 SL.
- Conditions
- Major Depressive Episode (MDE), Major Depressive Disorder (MDD), Depression
- Trial name
- HORIZON (NCT07621237)
- Testing
- TNX-102 SL
- Where
- 27 sites in United States
- Volunteers
- 360 people
- Sponsor
- Tonix Pharmaceuticals, Inc.
Depressive Disorder, Major, Anxiety Disorders
Evaluate the Quality of Life and Treatment of Anxiety Symptoms of Buspirone in Patients With Depression Disorders(BASIS)
Approximately 20 sites in Korea including the Catholic University of Korea, Yeouido St. Mary's Hospital. Patients with Depressive disorders taking a selective serotonin reuptake inhibitor (SSRI) antidepressant or Serotonin and…
- Trial name
- BASIS (NCT04770454)
- Where
- South Korea
- Volunteers
- 200 people
- Sponsor
- Boryung Pharmaceutical Co., Ltd
Depression, Anxiety
Evaluating Neuromodulation Technologies in Early Recovery
The study is an open-label comparative effectiveness clinical trial evaluating the impact of three neuromodulation treatment devices to improve the mental health and sobriety status of recovering substance abuse patients.
- Conditions
- Depression, Anxiety, Insomnia
- Trial name
- NCT01993277
- Testing
- Nexalin Brain Stimulator, Fischer Wallace Stimulator, David Delight Stimulator
- Where
- United States
- Volunteers
- 200 people
- Sponsor
- Behavioral Health of the Palm Beaches